Cyberport Venture Capital Forum (CVCF) 2025 Returns Under the Theme "The Innovation–Venture Nexus: Igniting Transformative Success"
Updated
January 8, 2026 6:34 PM
As the venture capital world recalibrates amid global uncertainty, Cyberport Venture Capital Forum (CVCF) 2025 returns on November 6-7 under the theme “The Innovation–Venture Nexus: Igniting Transformative Success”. PHOTO: CYBERPORT
The two-day forum will once again bring together global and local leaders to explore how technology, capital and collaboration intersect to drive the next wave of growth. Entrepreneurs, investors and innovators will exchange insights on artificial intelligence, digital assets and Web 3.0—technologies that are reshaping industries and redefining both risk and opportunity.
As industries face challenges from geopolitical shifts, regulatory changes and market volatility, CVCF will serve as a platform to address a defining question: How can innovation remain bold and visionary in an ever-evolving funding landscape? Through keynotes, panel discussions and interactive sessions, the forum will spotlight the transformative potential of technologies like artificial intelligence (AI), Web 3.0 and digital assets while offering practical strategies to turn disruption into market advantage.
With investor matching, power pitches, start-up clinics and workshops, CVCF 2025 offers a front-row seat to emerging markets across Asia, the Middle East, the United States and Europe, connecting forward-thinking investors with visionary entrepreneurs. It is not just a conference—it’s a bridge between ideas and investment designed to ignite breakthroughs and foster growth in the global innovation ecosystem. It provides a unique platform for startups and investors to navigate the complexities of today’s economy while seizing new opportunities for collaboration and growth.
To preview the conversations ahead, three speakers share perspectives on trends shaping the future of innovation, investment and entrepreneurship, setting the stage for the discussions that will unfold at CVCF 2025.
Co-founder and CEO, AIFT
Session: Riding the Middle East Momentum — Capitalizing Unique Innovation and Investment Strengths
As the Middle East accelerates its shift from oil dependence toward digital diversification, the region is becoming a focal point for blockchain and AI investment. In his upcoming session, Alvin Kwock will explore the region’s innovation potential — and here, he shares some of his views on the opportunities shaping that transformation.
Alvin Kwock, co-founder and CEO of AIFT, oversees operations across three verticals: AI and cybersecurity (Vulcan and Cymetrics), blockchain (OneInfinity and OneSavie) and pet and B2C (OneDegree). With local operations spanning Asia and the Middle East, AIFT is expanding rapidly.
When asked about the Middle East’s rapid rise as a global innovation hub, Kwock said that the region is shifting from a petroleum-dependent economy to one increasingly diversified through technology and innovation, with markets advancing blockchain and AI technologies. AIFT is prioritizing expansion in the UAE and Saudi Arabia, where AI investment and regulatory openness create immense potential. Hong Kong’s expertise in financial risk management acts as a “confidence anchor” for international markets, allowing AIFT to deliver compliant solutions tailored for emerging markets while developing Sharia-compliant, regulation-aligned technologies.
“Hong Kong’s storied expertise in financial risk management acts as a ‘confidence anchor’ for international markets.”
He also noted that the region’s accelerating digital adoption opens unique opportunities for AI, insurtech and fintech. The UAE and Bahrain’ embrace of virtual assets, combined with Hong Kong’s proven frameworks, provide a foundation for localized solutions. By integrating risk oversight and regulatory best practices, AIFT supports stable market growth and delivers specialized insurance to enhance resilience in emerging markets.
On managing geopolitical risk, Kwock explained that AIFT mitigates exposure through local partnerships, regulatory alignment and cultural understanding. By hiring Arab employees and ensuring operations align with Islamic values, AIFT strengthens Hong Kong–Middle East collaboration. This approach, he said, offers a blueprint for startups: prioritize local engagement and flexibility to balance risk and growth.
Founder, Hash Global Advisory Company Ltd.
Session: From Hype to Holdings — Where Smart Money Goes in Digital Assets 2025–2027
With institutional frameworks for Web 3.0 maturing, investors are increasingly focused on sustainable value creation. In his session, Kang Shen will discuss how smart capital is moving beyond speculation toward real-world utility—themes echoed in his reflections shared ahead of the forum.
Kang Shen, founder of Hash Global Advisory, applies value-investing principles to the Web 3.0 sector. A graduate of Fudan University and the University of Chicago Booth School of Business and a Chartered Financial Analyst (CFA), Shen has more than 20 years of financial industry experience with roles at the Industrial Bank of Japan, PIMCO and Bosera Asset Management.
On the tokenization of real-world assets, Shen observed that the RWA sector remains in its early phase of regulatory and infrastructure development. Over the next two years, as compliance systems mature, scalable projects with tangible value will emerge. For now, his approach remains cautious, focusing on fundamentals rather than inflated market narratives.
He also shared his optimism for three areas with the most potential upside: Web 3.0 Culture and Entertainment—including projects like Meet48 and Offgrid; Web 3.0 E-Commerce and Payments—with ventures such as WSPN, RD Technologies and Bitgoods; and On-Chain Data and Data Assets—such as Chainbase and Data Dance Chain. These, he noted, represent meaningful real-world applications of Web 3.0 technologies.
“Web 3.0 is currently undergoing a process of value realignment.”
Shen emphasized that Hash Global has always been committed to applying value-investing principles to the field of digital asset management. As early as 2019, the firm proposed using a monetary equation framework to evaluate ecosystem tokens and recently defined a new class—“Value-Functional Tokens”. He believes Web 3.0 is now undergoing a process of value realignment, where genuine utility will determine long-term worth.
Founder and CEO, Zhejiang Linctex Digital Technology Co., Ltd. (Style3D)
Session: Strategic Exits — IPO Paths for Expanding Rapid-Growth Companies
The fashion and textile industry is undergoing rapid digital transformation. Against this backdrop, Eric Liu will join CVCF 2025 to discuss strategic growth and expansion paths for fast-scaling companies.
Eric Liu, founder and CEO of Zhejiang Linctex Digital Technology Co., Ltd. (Style3D), holds dual master’s degrees in applied computing and molecular biology from VUB University in Belgium and a PhD in Electronic Information Engineering from Zhejiang University. A serial entrepreneur in the textile industry, Liu founded Style3D to drive digital transformation through AI and 3D technology.
He explained that Style3D’s fusion of AI and 3D technology builds a full-chain digital ecosystem. AI-driven design tools powered by large language models shorten design cycles from weeks to hours, while 3D simulation reduces prototyping costs by 30 percent. The company’s self-developed simulation engine supports virtual fashion shows and sustainability initiatives by optimizing fabric usage.
“Style3D’s fusion of AI and 3D technology builds a full-chain digital ecosystem.”
On the company’s origins, Liu said that traditional fashion R&D cycles are slow and costly. By integrating AI for pattern generation and 3D for design-to-production links, Style3D overcomes these barriers. With over 200 core patents and an extensive database of 2.3 million fabric properties and 1.2 million garment templates, the company leads digital fashion innovation.
Looking ahead, Liu noted that Style3D reinvests 40 percent of annual revenue into R&D, develops AI-driven trend prediction tools and expands innovation hubs in Paris and Milan. By leading the standardization of “3D Digital Fashion Infrastructure”, Style3D is setting the industry benchmark for the next era of intelligent manufacturing.
As global innovators prepare to gather at CVCF 2025, the forum promises to ignite ideas, discoveries and partnerships that will shape the future of technology and investment. From cutting-edge insights to practical strategies, the conversations starting here are just the beginning of a journey to redefine what’s possible in the global innovation ecosystem.
.jpg)
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.